Andre Peisker1, Gregor Franziskus Raschke2, Arndt Guentsch3, Paul Luepke3, Korosh Roshanghias2, Stefan Schultze-Mosgau2. 1. Department of Cranio-Maxillofacial & Plastic Surgery, Jena University Hospital, Erlanger Allee 101, 07749, Jena, Germany. andre.peisker@med.uni-jena.de. 2. Department of Cranio-Maxillofacial & Plastic Surgery, Jena University Hospital, Erlanger Allee 101, 07749, Jena, Germany. 3. Department of Surgical Sciences, Marquette University, School of Dentistry, Milwaukee, Wisconsin, 53201-1881, USA.
Abstract
OBJECTIVES: The duration and the frequency of follow-up after treatment of oral squamous cell carcinoma are not standardized in the current literature. The purpose of this study was to evaluate our local standard post-treatment and follow-up protocol. MATERIALS AND METHODS: Overall, 228 patients treated curatively from 01/2006 to 07/2013 were reviewed. To evaluate the follow-up program, data on the secondary event were used. To determine risk groups, all patients with tumor recurrence were specifically analyzed. Relapse-free rate were estimated by the Kaplan-Meier product limit method. The chi-square test was used to identify independent risk factors for tumor relapse. RESULTS: In total, 29.8 % patients had a secondary event. The majority of the relapse cases (88.2 %) were detected within 2 years postoperatively, 61.8 % of them within the first year. Most events were local recurrences (34.7 %). UICC-stage IV was significantly associated with tumor recurrence (p = 0.001). Gender (p = 0.188), age (p = 0.195), localization (p = 0.739), T-stage (p = 0.35), N-stage (p = 0.55), histologic grade (p = 0.162), and tobacco and alcohol use (p = 0.248) were not significantly associated with tumor recurrence. Patients with positive neck nodes relapsed earlier (p = 0.011). The majority of relapses (86.3 %) were found in asymptomatic patients at routine follow-up. CONCLUSIONS: The results of this study suggest an intensified follow-up within the first 2 years after surgery. CLINICAL RELEVANCE: Given the higher relapse rate of patients exhibiting an UICC-stage IV and/or positive neck nodes, it seems to be from special interest to perform in this group a risk-adapted follow-up with monthly examinations also in the second year.
OBJECTIVES: The duration and the frequency of follow-up after treatment of oral squamous cell carcinoma are not standardized in the current literature. The purpose of this study was to evaluate our local standard post-treatment and follow-up protocol. MATERIALS AND METHODS: Overall, 228 patients treated curatively from 01/2006 to 07/2013 were reviewed. To evaluate the follow-up program, data on the secondary event were used. To determine risk groups, all patients with tumor recurrence were specifically analyzed. Relapse-free rate were estimated by the Kaplan-Meier product limit method. The chi-square test was used to identify independent risk factors for tumor relapse. RESULTS: In total, 29.8 % patients had a secondary event. The majority of the relapse cases (88.2 %) were detected within 2 years postoperatively, 61.8 % of them within the first year. Most events were local recurrences (34.7 %). UICC-stage IV was significantly associated with tumor recurrence (p = 0.001). Gender (p = 0.188), age (p = 0.195), localization (p = 0.739), T-stage (p = 0.35), N-stage (p = 0.55), histologic grade (p = 0.162), and tobacco and alcohol use (p = 0.248) were not significantly associated with tumor recurrence. Patients with positive neck nodes relapsed earlier (p = 0.011). The majority of relapses (86.3 %) were found in asymptomatic patients at routine follow-up. CONCLUSIONS: The results of this study suggest an intensified follow-up within the first 2 years after surgery. CLINICAL RELEVANCE: Given the higher relapse rate of patients exhibiting an UICC-stage IV and/or positive neck nodes, it seems to be from special interest to perform in this group a risk-adapted follow-up with monthly examinations also in the second year.
Authors: Matthias Adrianus Wilhelmus Merkx; Joris Jan Martijn van Gulick; Henri August Marie Marres; Johannus Hendrikus Antonius Maria Kaanders; Ingolv Bruaset; André Verbeek; Peter Christianus Martinus de Wilde Journal: Head Neck Date: 2006-01 Impact factor: 3.147
Authors: K Yuasa; T Kawazu; N Kunitake; S Uehara; J Omagari; K Yoshiura; E Nakayama; S Kanda Journal: AJNR Am J Neuroradiol Date: 2000 Jun-Jul Impact factor: 3.825
Authors: C J Flynn; N Khaouam; S Gardner; K Higgins; D Enepekides; J Balogh; R MacKenzie; S Singh; J Davidson; I Poon Journal: Clin Oncol (R Coll Radiol) Date: 2010-07-21 Impact factor: 4.126
Authors: Ardalan Ebrahimi; Jonathan R Clark; Wan Jing Zhang; Michel S Elliott; Kan Gao; Christopher G Milross; Kerwin F Shannon Journal: Head Neck Date: 2010-10-21 Impact factor: 3.147
Authors: Jens Overgaard; Hanne Sand Hansen; Lena Specht; Marie Overgaard; Cai Grau; Elo Andersen; Jens Bentzen; Lars Bastholt; Olfred Hansen; Jørgen Johansen; Lisbeth Andersen; Jan F Evensen Journal: Lancet Date: 2003-09-20 Impact factor: 79.321
Authors: A Peisker; G-F Raschke; M-D Fahmy; A Guentsch; K Roshanghias; J Hennings; S Schultze-Mosgau Journal: Med Oral Patol Oral Cir Bucal Date: 2017-05-01